The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
The interim efficacy readout, involving around 170 participants with 15-month data, remains on track for the end of March 2026
Transcenta will grant EirGenix a non-exclusive license to its Highly Intensified Continuous Bioprocessing (HiCB) platform
Astal estimates the collaboration will generate incremental revenue of approximately Rs. 300 crore upon implementation
The company plans to use the newly secured funding to expand the indications of its Grabody platform into high-unmet-need areas
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
The primary goal of the collaboration is joint research into trending and next-generation molecules
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
Singlera and Pure Medical will team up with local universities, hospital networks, and national healthcare systems across Western Europe for research studies
Subscribe To Our Newsletter & Stay Updated
